Rafferty Asset Management
MDGL icon

Rafferty Asset Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Rafferty Asset Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.15M Sell
5,858
-4,594
-44% -$2.35M 0.01% 531
2026
Q1 		$5.47M Sell
10,452
-78
-0.7% -$37.3K 0.02% 335
2025
Q4 		$6.13M Sell
10,530
-8,185
-44% -$4.18M 0.02% 370
2025
Q3 		$8.58M Sell
18,715
-5,818
-24% -$2.17M 0.03% 309
2025
Q2 		$7.42M Sell
24,533
-5,369
-18% -$1.6M 0.02% 327
2025
Q1 		$9.9M Sell
29,902
-3,221
-10% -$1.06M 0.04% 263
2024
Q4 		$10.2M Sell
33,123
-11,501
-26% -$3.23M 0.04% 280
2024
Q3 		$9.47M Buy
44,624
+8,206
+23% +$2.1M 0.03% 291
2024
Q2 		$10.2M Buy
36,418
+501
+1% +$119K 0.04% 280
2024
Q1 		$9.59M Sell
35,917
-7,182
-17% -$1.69M 0.04% 276
2023
Q4 		$9.97M Sell
43,099
-2,224
-5% -$389K 0.04% 279
2023
Q3 		$6.62M Buy
45,323
+14,067
+45% +$2.65M 0.04% 333
2023
Q2 		$7.22M Buy
31,256
+3,121
+11% +$845K 0.04% 329
2023
Q1 		$6.82M Sell
28,135
-77,255
-73% -$21.1M 0.05% 301
2022
Q4 		$30.6M Buy
105,390
+39,469
+60% +$3.86M 0.26% 66
2022
Q3 		$4.28M Buy
65,921
+34,761
+112% +$2.42M 0.05% 362
2022
Q2 		$2.23M Sell
31,160
-15,127
-33% -$1.11M 0.02% 439
2022
Q1 		$4.54M Buy
46,287
+9,740
+27% +$821K 0.03% 411
2021
Q4 		$3.1M Buy
36,547
+5,091
+16% +$418K 0.02% 528
2021
Q3 		$2.51M Buy
31,456
+7,291
+30% +$630K 0.02% 563
2021
Q2 		$2.35M Sell
24,165
-4,110
-15% -$487K 0.01% 640
2021
Q1 		$3.31M Buy
28,275
+21,301
+305% +$2.48M 0.02% 425
2020
Q4 		$775K Sell
6,974
-3,532
-34% -$432K 0.01% 580
2020
Q3 		$1.25M Buy
10,506
+2,903
+38% +$315K 0.02% 544
2020
Q2 		$861K Buy
+7,603
New +$748K 0.01% 586
2020
Q1 		– Sell
-15,679
Closed -$1.43M – 728
2019
Q4 		$1.43M Sell
15,679
-18,551
-54% -$1.8M 0.02% 468
2019
Q3 		$2.95M Sell
34,230
-4,989
-13% -$468K 0.05% 233
2019
Q2 		$4.11M Buy
39,219
+7,708
+24% +$826K 0.07% 204
2019
Q1 		$3.95M Buy
+31,511
New +$3.92M 0.06% 172

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Rafferty Asset Management's MDGL Position: Q2 2026 in Review

Rafferty Asset Management reduced its Madrigal Pharmaceuticals (MDGL) stake by 44% in Q2 2026, selling an estimated $2.35M and leaving 5,858 shares worth $3.15M. The position accounts for 0.01% of the portfolio, ranked #531.

Rafferty Asset Management first reported a position in MDGL in Q1 2019 and has held it in 29 quarters since. The position peaked at $30.6M in Q4 2022. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Rafferty Asset Management held 5,858 shares of Madrigal Pharmaceuticals worth $3.15M as of Q2 2026.
  • Rafferty Asset Management sold 4,594 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.35M.
  • Madrigal Pharmaceuticals made up 0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #531 holding.
  • Rafferty Asset Management first reported a position in Madrigal Pharmaceuticals in Q1 2019 and has held it in 29 quarters since.
  • Rafferty Asset Management's Madrigal Pharmaceuticals position peaked at $30.6M in Q4 2022.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.